The Top 10 Tweets from #JPM13 (And What They Tell Us)

Posted by: in Healthcare Insights, Medical Communications, Social Media Insights & Trends on January 11, 2013

The J.P. Morgan Health Care Conference is over, and the crowds have dissipated from all of the conference’s hotspots: the hallway outside the Colonial Ballroom, the bar at the Clift, that Starbucks around the corner. The crowds, too, have left Twitter. This year, more than 9,000 tweets were posted referencing the #JPM13 hashtag, more than tripling last year’s chatter. With so much said, we thought that sifting through the information could give a unique perspective on the biopharm confab.

To figure out what ideas really stuck, we pulled the 10 most rewteeted lines of the conference. Here they are (and what they say about the meeting):

@genentech: “Nice antibody. Wanna conjugate?” #jpmpickuplines #jpm13

San Francisco Business Times reporter Ron Leuty started the pick-up lines meme, but it was a perfectly crafted tweet from Genentech that stole the show: on-topic, geeky and surprising. When companies show their human side, they win, and Genentech proved that this week.

@lindaavey: “Don’t call it big data, call it good science” Lon Cardon, GSK. #BigData #JPM13

Big data was a big deal this year, and so was big pharma. With venture money harder and harder to secure, all eyes were on how cash-rich pharmaceutical companies would play the biotech wave. The Cardon quote came from a thoughtful FierceBiotech breakfast panel.

@2healthguru: ‘With healthcare reform we are positioned to perform well..’ Greg Roth, CEO @TeamHealth #jpm13

This tweet proved that Twitter can be a perfect niche medium. Though the TeamHealth tweet picked up plenty of RTs, it was mostly by little-followed accounts. The company may not have made waves at J.P. Morgan, but the people who needed to see the news saw it.

@ceels66: Every orphan drug co presentation I’ve been in at #JPM13 has been packed. Super hot space rt now so obvi we’ll be doing panel at #BIOCEO13.

Some trends are too clear to ignore. 2012 was a year where some new mass-market drugs ran into trouble, but I’m not sure anyone has ever written the phrase “struggling orphan-drug maker.”

@illumina: #HiSeq2500 enhancements in 2H13 will support 2×250 bp, 300 Gb in rapid run mode #JPM13

Illumina knows its audience. They know their audience, and even if the Wall Street Journal wasn’t paying attention to their technological improvements, plenty of genomics researchers were.

@daphnezohar: Widget to track twitter conversations around the 3 HC conferences in SF this week: #JPM13 #BTS13 @appeering

@appeering, which powered my post on Monday, was definitely the most-buzzed-about Twitter-tracking tool of the conference. And when you have 9,000 tweets, anything that turbocharges the sifting process is a blessing.

@illumina: Illumina acquires SF-based Moleculo Inc., for novel sample prep & analysis, synthetic read lengths up to 10 kb #JPM13

Illumina is the only Twitter handle to appear on the list twice. But check out the level of engagement in their Twitter feed: it’s clear that the company understands that Twitter is a two-way communications channel.

@DrJoonYun: Healthcare needs a design thinker like Steve Jobs to disrupt our industry. #JPM13

Yes. Yes we do.

@rleuty_biotech: “It’s not the size of the clinical trial that counts — it’s the outcome.” #jpmpickuplines #JPM13

It’s only fair that Leuty made the top-10 list, given that his pick-up lines brainchild dominated the meeting. About 1 in every 10 #JPM13 tweets was a pick-up line.

@adamfeuerstein: My preview of next week’s J.P. Morgan Healthcare Conference #JPM13 $$

TheStreet’s Feuerstein was again the digital hub of the meeting. No one tweeted more, garnered more retweets, or used more colorful language. Love him or hate him (we love him, mostly), there’s no questioning Adam’s influence when it comes to setting the agency for J.P. Morgan online.

Of course, the J.P. Morgan meeting is so diverse that it’s impossible to capture in 10 tweets (or even 9,000, for that matter). This misses the rise of Celgene as industry bellwether, the huge amount of attention paid to obesity drugs and the increasingly important role of payers and health systems in changing behaviors within the industry. But it does give a window into what, exactly, everyone in the back of the room was doing when they pulled out their iPads.

(Also: to catch my other J.P. Morgan wrapup, check out the post on the BrewLife What’s Brewing blog.)

By: Brian Reid

Brian Reid is a managing director at W2O Group, where he oversees influencer relations. He is a former journalist who believes content really is king.

Find me on: Twitter
Pre-Commerce Check out W2O Group President Bob Pearson's new book, Pre-Commerce, in which he shares ideas for leaders to engage directly with customers to shape their brand and marketplace success. Now available for order on! Join the conversation #precommerce.

0 Responses

Stay in touch with the conversation, subscribe to the RSS feed for comments on this post.

Some HTML is OK


(required, but never shared)

or, reply to this post via trackback.